Neovasc Inc (US) (NVCN) Scheduled to Post Quarterly Earnings on Wednesday

Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) is scheduled to release its earnings data after the market closes on Wednesday, March 28th.

Shares of Neovasc Inc (NASDAQ:NVCN) opened at $0.11 on Monday. The stock has a market cap of $8.69, a price-to-earnings ratio of 0.46 and a beta of 0.52. Neovasc Inc has a 12-month low of $0.10 and a 12-month high of $2.04.

How to Become a New Pot Stock Millionaire

Several research firms have issued reports on NVCN. ValuEngine lowered shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered shares of Neovasc Inc (US) from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, Canaccord Genuity restated a “buy” rating and issued a $1.05 price target on shares of Neovasc Inc (US) in a research report on Friday, January 19th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.95.

ILLEGAL ACTIVITY WARNING: “Neovasc Inc (US) (NVCN) Scheduled to Post Quarterly Earnings on Wednesday” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3300806/neovasc-inc-us-nvcn-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Neovasc Inc (US) Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Earnings History for Neovasc Inc (US) (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jewett-Cameron Trading Co  Stake Held by Fort Nelson Partners, LP
Jewett-Cameron Trading Co Stake Held by Fort Nelson Partners, LP
Greenhill & Co.  and GAMCO Investors  Critical Review
Greenhill & Co. and GAMCO Investors Critical Review
STRAKS Tops 1-Day Volume of $24,012.00
STRAKS Tops 1-Day Volume of $24,012.00
KlondikeCoin  Achieves Market Capitalization of $0.00
KlondikeCoin Achieves Market Capitalization of $0.00
Roku  and Its Competitors Head to Head Survey
Roku and Its Competitors Head to Head Survey
Pentair  vs. Metso  Financial Analysis
Pentair vs. Metso Financial Analysis


© 2006-2018 Ticker Report. Google+.